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Background 
Prostate cancer is the most common male cancer and one of the leading causes 
of cancer-related morbidity and death [1]. In prostate cancer natural history, 
approximately 10% of patients will develop a castration-resistant disease, with a 
median survival of 2 years [2]. The majority of patients with metastatic Castration-
Resistant Prostate Cancer (mCRPC) has a radiological evidence of bone metastases, 
which are the main cause of pain and disability, leading to a reduced quality of life. 
Moreover, in patients with mCRPC bone metastases are independently associated to 
mortality [3].
Over last years, several novel drugs for CRPC have been introduced, such as the new 
taxan agent cabazitaxel, immunotherapy (sipuleucel-T), RANK-L inhibitor denosumab, 
androgen biosynthesis inhibitors (abiraterone acetate) and androgen receptor 
antagonists (enzalutamide). These promising antitumoral agents have changed 
therapeutic management of CRPC patients, although there is still the need to deϐine an 
Abstract
Ra-223 dichloride is a fi rst-in-class alpha-emitting radiopharmaceutical recently introduced into clinical 
practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone 
metastases. Due to the proven benefi t on Overall Survival and the favorable toxicity profi le, Ra-223 therapy 
is gaining widespread use in both US and Europe. In this article, we describe the routinary management of 
patients undergoing Ra-223 treatment in our Institution.
Currently, Ra-223 therapy is indicated for 6 intravenous injections (55 kBq per kg of body weight) 
administered every 28 days. In comparison to other radiopharmaceuticals, Ra-223 handling and administration 
do not need any additional training for authorized users. Due to the minimal external dose rate emission, 
Ra-223 dichloride can be delivered in an outpatient setting. Moreover, no particular precautions other than 
standard hygiene measures must be taken by patients’ family members or caregivers. Ra-223 therapy is 
associated to a favorable hematologic toxicity profi le, while non-hematologic adverse events are generally 
mild and easy to manage. 
Given the favorable toxicity profi le of this treatment, clinical trials are currently ongoing to evaluate effi  cacy 
and safety of Ra-223 treatment in combination or sequence with recently approved drugs such as abiraterone 
acetate, enzalutamide and sipuleucel-T. In addition, the recent interest in Ra-223 bone lesion dosimetry 
could open the way to a dosimetric-based therapeutic approach with Ra-223. In this new scenario, results of 
these promising clinical trials may help clarifying the optimal sequencing of new therapeutic possibilities for 
metastatic CRPC and the appropriate eligibility criteria for Ra-223 treatment in oncologic patients.
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appropriate sequencing for their application in order to maximize patient beneϐit and 
minimize costs [4].
In this evolving scenario, a ϐirst-in-class alpha-emitting radionuclide, Ra-223 
dichloride, has been recently approved for the treatment of men with mCRPC with 
symptomatic bone metastases and no known visceral metastases. FDA approval of Ra-
223 came in May 2013 as a result of the ϐindings of the international, randomized, 
double-blind Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) Phase III trial 
that evaluated efϐicacy on Overall Survival of Ra-223 treatment versus placebo in 
patients with mCRPC [5].
Ra-223 is a short-lived (half-life 11.4 days) alpha emitter, which decays to stable 
lead through a cascade of short-lived alpha-emitting and beta-emitting progeny. 
Thanks to its analogy to calcium, Ra-223 targets areas of increased bone turnover 
delivering high-energy, short-range alpha particles. Ra-223 emits predominantly 
alpha-particle radiation (95.3% of total emitted activity), 3.6% of beta particles and 
1.1% of gamma rays. Alpha particles are responsible for double stranded breaks in cell 
DNA, causing a local cytotoxic effect [6,7]. Notably, alpha-particle radiation has a very 
short penetration range (<100 μm), so there is limited damage to the bone marrow 
[8-10]. Results of the ALSYMPCA trial have shown a signiϐicant impact of Ra-223 
therapy on Overall Survival (OS) and a delay in median time to the ϐirst Symptomatic 
Skeletal Event (SSE), associated to a relevant bone pain palliation. In addition, Ra-223 
treatment was characterized by a low toxicity proϐile in terms of both hematologic and 
non-hematologic adverse events, which were mild to moderate in intensity [5]. 
Survival beneϐit distinguishes Ra-223 from other bone-targeted therapies, such 
as local radiation, radioisotopes Sr-89 and Sm-153-EDTMP, zoledronic acid and 
denosumab, which have demonstrated to be effective on bone pain palliation but have 
not shown an improvement in Overall Survival [11]. 
To date, Ra-223 beneϐits and recommendations for use are included in all major 
European and North American treatment guidelines for CRPC [12-18]. Since its 
introduction in Italian pharmacopoeia in May 2015, Ra-223 therapy is gaining 
widespread use in clinical practice. Currently, Ra-223 dichloride therapy is addressed to 
patients with Castration-Resistant Prostate Cancer with symptomatic bone metastases 
and no evidence of visceral disease (excepted for malignant lymphadenopathies not 
exceeding 3 cm in short-axis diameter). The approved dose regimen of Ra-223 consists 
in an activity of 55 kBq per kg of body weight administered in 6 intravenous injections 
at 4-weeks intervals [19]. This paper describes a single-center clinical experience in 
the routinary management of Radium-223 treatment.
Patient referral and management
Italian law states that a nuclear physician (or a radiation oncologist in structures 
not equipped with a nuclear medicine department) would administer Ra-223 and that 
this would take place within a licensed Nuclear Medicine or Radiology department. 
Italian regulation requires that the Nuclear Medicine department would have obtained 
permission for detention of the alpha-emitting radiopharmaceutical Radium-223.
Patients eligible to receive Radium-223 are generally referred from medical 
oncologists, radiation oncologist or urologists to an authorized Nuclear Medicine 
department for consultation and administration. In our routine practice, once 
the patient has been referred to the Nuclear Medicine unit for Ra-223 therapy, he 
undergoes a ϐirst clinical evaluation to assess the clear eligibility to treatment. During 
consultation, the patient is extensively informed on the aim of Ra-223 therapy and 
about possible treatment-related adverse events. Informed consent form is then 
obtained from the patient.
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In order to be eligible to Ra-223 therapy, the patient must present adequate 
hematologic parameters (Hb≥10 g/dl, Absolute Neutrophil Count≥15x109/L, 
Platelets≥100x109/L). Ra-223 hematologic toxicity proϐile is highly favorable due to the 
very short penetration range of alpha particles, which results in a limited irradiation 
of normal bone marrow [5,8-10,20]. Hematologic evaluation must be repeated before 
subsequent Ra-223 cycles, where ANC should be ≥10x109/L and Platelets ≥50x109/L. 
In our routine activity, complete blood counts are obtained on the 10th and 24th day 
after Ra-223 injection; in this last blood sample PSA and total Alkaline Phosphatase 
(t-ALP) are also evaluated. 
Non-hematologic adverse events such as diarrhea, fatigue and nausea are 
more commonly observed, and are mild to moderate in intensity. A bone pain ϐlare 
phenomenon can be experienced by patients shortly after Ra-223 injection, but it is 
generally limited in time (2-3 days). These adverse effects are all easily manageable 
with symptomatic and supportive treatments. As assessed in Ra-223 biokinetics 
studies, this radiopharmaceutical is mainly excreted through gut, so a variable degree 
of intestinal inϐlammation is expected [21]. For this reason, eligible patients must not 
present a condition of chronic Inϐlammatory Bowel Disease. Within one month before 
ϐirst Ra-223 treatment, baseline burden of bone disease is evaluated with a whole-body 
Tc-99m diphosphonate bone scan. Pain score is evaluated with Brief Pain Inventory 
(BPI) 0-10 Numeric Rating Scale at baseline and after each Ra-223 administration. To 
further evaluate pain response and Quality of Life endpoints, European Organization 
for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC 
QLQ-C30) and the bone metastasis module (QLQ-BM22) are submitted to patients 
at baseline and after each treatment and analyzed according to published guidelines 
[22]. Edmonton Symptom Assessment System (ESAS) is used with the same timing to 
evaluate clinical response to treatment [23].
At the time of the ϐirst clinical evaluation in the Nuclear Medicine facility, patients 
generally underwent different anti-neoplastic treatments. ALSYMPCA trial showed that 
Ra-223 produced a survival beneϐit in both chemo-naïve patients and in the docetaxel 
pre-treated subgroup. These ϐindings were further validated in a prespeciϐied subgroup 
analysis of ALSYMPCA patients that conϐirmed the highly favorable safety proϐile of 
Ra-223 verifying the low incidence of myelosuppression, irrespective of previous 
docetaxel use [24]. In our clinical experience, there is a quite balanced proportion 
between chemo-naïve population and patients pre-treated with docetaxel. In our 
centre, regular communication between referring physicians and the treating nuclear 
medicine physicians have been established to keep all parties informed of patients’ 
progress. Furthermore, a dedicated Ra-223 telephone line has been activated to allow 
patients to connect to the nuclear medicine physicians.
Radiopharmaceutical ordering
As assessed by Italian Drug Agency AIFA, Ra-223 must be administered in a public 
hospital facility. Pharmaceutical reimbursement to hospital is assured by Italian 
National Healthcare System. 
In our centre routine, every single Ra-223 treatment is ordered approximately 14 
days before the scheduled treatment date. Ra-223 activity is required as a patient-
speciϐic dosage unit according to patient’s weight. The drug dose is shipped to the 
licensed user from the production site in Norway. The shipping time is about 10-14 
days. At the time of shipment from the manufacturer, the vial contains 14 MBq of Ra-
223. The shipping box arrives with a glass vial containing 6 ml of Ra-223 dichloride 
solution for injection stored in a lead container, shipping documents and a table for 
decay correction according to physical decay of the radionuclide. Ra-223 dichloride 
comes in a ready-to-use glass vial as a sterile, non-pyrogenic, clear and colorless 
solution for intravenous administration. Notably, it doesn’t require any kit preparation 
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prior to administration. The drug product has a shelf-life of 28 days from production 
day and must be stored at room temperature in its lead container. It must be placed in 
a secure facility with limited access until administration.
Radiopharmaceutical preparation
The accurate measurement of Ra-223 activity is assured by calibration of dose 
calibrators using a National Institute of Standard and Technology (NIST) reference 
standard which is provided to authorized users by Bayer Healthcare. In 2015, primary 
NIST dose calibrator standards for Ra-223 have been revised due to erroneously 
activity readings, about 10% lower than expected [25]. Updated secondary NIST 
reference standards have been introduced into clinical practice from January 2016 
[26]. Each center must determine the Ra-223 dial setting on their own dose calibrator. 
For the routine accuracy check, the reference source is placed in the dose calibrator 
and the activity is recorded. Values should be within the allowable tolerance of 10%. 
Radiopharmaceutical preparation should be carried out within a shielded contained 
workstation equipped with laminar air ϐlow, under aseptic conditions. To assist 
department workϐlow, one deϐined day each week is dedicated to Ra-223 treatment. 
When feasible, two staff members should be present at the time of injection, to allow one 
staff member to prepare the injection while the other takes care of the patient. Ideally, 
Ra-223 preparation for injection should start once patient attendance is conϐirmed 
to avoid wasting a Ra-223 dose. It is worthy to remember that the survival beneϐit 
with Ra-223 in the ALSYMPCA study was observed with some ϐlexibility in the dosing 
schedule: the 4-weekly injections could be administered within a window of -3 days 
to +7 days from scheduled treatment date. When last-minute cancellations occur and 
patient postponement is not possible, it may be possible to switch orders to another 
patient of similar weight to avoid wasting the radium-223 dose. On the day scheduled 
for treatment, Ra-223 dosage is determined according to current patient’s weight. 
The volume to be drawn from the vial is calculated knowing initial concentration (6,6 
MBq/6 mL at reference date) and the date of calibration assessed through the decay 
table provided with the radionuclide. The required volume is then drawn in a syringe 
and the ϐinal dosage is veriϐied in the dose calibrator.
During radiopharmaceutical manipulation, care must be taken to prevent spillage 
from occurring. Stabin and Siegel evaluated the potential risk of exposure due to 
an occasional contamination occurred during Ra-223 handling. They assessed that 
there are no major radiation safety concerns regarding both external exposure (dose 
to whole body and direct skin contamination were analyzed) and internal exposure 
(mainly due to inhalation of daughter radionuclide Rn-219) [27]. Furthermore, a 
study from Denmark suggests that spills do not lead to signiϐicant fractions of airborne 
activity [28]. Due to the presence of a minimal Ra-223 gamma-emission component, 
no additional alpha-radiation speciϐic equipment is needed to assess an event of 
contamination.
Radium-223 administration
As assessed by Italian regulation, Ra-223 can be delivered in an outpatient setting. 
Radiopharmaceutical is prepared according to current patient’s weight as described 
above. Owing to the nature of alpha-particles radiation, it is easily shielded compared 
with other types of ionizing irradiation. As a result, no particular shielding is required 
for the syringe containing Ra-223 dose. The administration is performed through an 
intravenous (IV) line. The IV access is veriϐied by a ϐlush of isotonic saline and Ra-
223 dichloride is administered as a slow injection over 1-2 minutes. After infusion, 
the intravenous access is ϐlushed again with saline. After administration, the syringe is 
re-measured in the dose calibrator to check the actual amount of injected radioactivity. 
As can be noticed, no additional training is required for authorized personnel to safely 
handle and administer Ra-223 dichloride.
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Patients injected with Ra-223 are immediately releasable due to the minimal 
external dose rate emission. Indeed, external exposure to others derived from photon 
emission from the patient is very low due to attenuation in the patient’s body. As 
assessed by Dauer et al, the estimated dose to a member of the public is expected to 
be below 1 mSv and below 5 mSv to health care workers [29]. Regarding potential 
exposure of medical staff, exposure rate constants of Ra-223 is comparable to Tc-99m 
as assessed by Smith and Stabin, while exposure from patients to others is very low 
compared to that of Technetium, so that a patient treated with Ra-223 is immediately 
releasable as per applicable guidelines on patient dose rates [30]. Because of Ra-223 
excretion is predominantly through feces, contamination and intake of activity by 
family members or caregivers is unlikely. Furthermore, only 5% of injected activity 
is excreted through kidneys, subsequently the patient should be recommended to use 
standard daily hygiene measures [21]. 
Waste and disposal
Ra-223 is disposed of in a suitable clinical radioactive waste stream after an 
appropriate amount of time. Since there are no long-lived radioactive waste products 
after decay, Ra-223 can be disposed of by decay-in-storage. The used vial must be stored 
inside its lead container in a secure facility. The disposable equipment used during 
administration must be treated as a short-lived radioactive waste and is disposed of in 
accordance to Nuclear Medicine Department procedures. The remains of radioactivity 
and contaminated material are disposed in accordance with local regulations and 
hospital radiation safety measures.
Biomarkers
As stated in ALSYMPCA trial, PSA is not an objective biomarker in assessing Ra-
223 efϐicacy [5]. Furthermore, a PSA ϐlare phenomenon has been described by various 
authors [31,32]. This condition can be misinterpreted as therapeutic failure. We 
recommend not to discontinue Ra-223 therapy on the occurrence of a PSA level rise, 
not supported by a radiological report of disease progression, to prevent a premature 
discontinuation of a potentially effective therapy. Several studies on prostate cancer 
patients assessed that total serum ALP is a more reliable parameter than PSA in 
evaluating bone disease [33,34]. A separated analysis of CRPC patients treated with Ra-
223 in phase II studies demonstrated that a decline in serum t-ALP during treatment 
was associated with a signiϐicantly better Overall Survival [35], suggesting that total 
ALP may be a useful dynamic marker to monitor as an indication of disease status. 
Further exploratory analysis of ALSYMPCA data on t-ALP dynamics during Ra-223 
treatment conϐirmed that t-ALP decline at 12 weeks correlated with longer OS, but this 
biomarker did not meet statistical requirements as surrogate marker for survival [36]. 
Bone imaging
In order to assess bone lesions dynamics during treatment, a Tc-99m diphosphonate 
bone scan is performed at baseline and repeated every two Ra-223 cycles. Follow-
up bone scans are repeated 3, 6 and 12 months after sixth Ra-223 treatment. Bone 
scans are evaluated by two experienced nuclear physicians. The extent of bone disease 
is expressed according to Soloway classiϐication [37]. In the majority of patients 
undergoing Ra-223 therapy, mid-term bone scans show a stability of bone lesions. In 
our clinical experience with Ra-223 dichloride, only in follow-up bone scans few cases 
of radiotracer uptake regression were observed. 
Notably, bone scans during Ra-223 treatment may also demonstrate a bone ϐlare 
phenomenon. Enhanced Tc-99m diphosphonate uptake can be observed because of 
an increased osseous metabolism surrounding bone metastases due to alpha particles 
irradiation. Physicians should be aware of his phenomenon to avoid discontinuation of 
treatment in the hypothesis of disease progression. 
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However, evaluation of Ra-223 therapeutic efϐicacy through bone imaging (Tc-99m 
diphosphonate bone scintigraphy versus F-18 ϐluoride PET) is still a matter of debate.
Treatment discontinuation 
Burden of bone disease at baseline affects development of hematologic adverse 
events during Ra-223 treatment. A post-hoc analysis of ALSYMPCA patients 
demonstrated that a greater extent of bone disease on bone scan and total ALP >220 U/l 
at baseline are correlated to an increased risk of developing grade 2-4 anemia during 
Ra-223 treatment [38]. Patients developing grade 3-4 anemia or thrombocytopenia 
should be supported with blood or platelets transfusions in order to continue Ra-223 
treatment. There is, in fact, a signiϐicant correlation between the number of completed 
Ra-223 cycles and patients’ outcome, as assessed in a recent retrospective analysis. 
The study, conducted on 110 patients treated with Ra-223 in the US Expanded Access 
Program, showed that patients who completed six Ra-223 cycles despite disease 
progression presented a longer median OS than patients who discontinued Ra-223 
therapy due to progression [39]. 
If a sustained Bone Marrow Failure (BMF) is observed, a delay in Ra-223 therapy is 
accepted to recover of adverse events. As stated in ALSYMPCA trial, the delay should 
not exceed 28 days from the scheduled treatment date, that is to say 8 weeks from 
the last Ra-223 injection. After this period has passed, if recovery from BMF has 
not been reached, treatment with Ra-223 should be discontinued. It is, however, on 
behalf of medical oncologist and nuclear medicine physician to decide if the patient’s 
clinical conditions allow to continue Ra-223 treatment.Conϐirming literature data, 
in our clinical experience most common reasons for discontinuing treatment are 
disease progression, grade 3-4 anemia and death [40]. To date, in our centre 588 223Ra 
cycles were delivered to 125 pts (mean age 73y, mean Gleason Score 8, mean ECOG 
Performance Status 1.1). Discontinuation rate was 40% due to disease progression 
(46%), bone marrow failure (23%) and death (31%).
Follow-up
Patients who completed six Ra-223 cycles enter a follow-up program consisting in 
evaluation of complete blood counts, PSA, total ALP values and bone scan after 3, 6 and 
12 months from the last Ra-223 administration. Patients who underwent a Choline 
PET/CT scan before Ra-223 treatment are asked to be repeated it a month after last 
Ra-223 cycle and then accordingly to oncologic indications.
Current status and future perspectives
Radiometabolic therapy with Ra-223 dichloride is a promising treatment for 
patients with CRPC and symptomatic bone metastases. This new therapy is a proper 
example of multidisciplinary management of oncologic patients. Medical oncologist, 
urologist, radiation oncologist, nuclear medicine physician and radiologist should 
cooperate in the management of CRPC patients to identify the best therapeutic 
options in the appropriate sequencing. Given the favorable toxicity proϐile of this 
radiopharmaceutical and the non-overlapping mechanism of action, a signiϐicant 
interest is growing around possible associations of Ra-223 with other antitumoral 
drugs, characterized by a complementary pharmacological pathway. Clinical trials are 
currently ongoing to evaluate safety and efϐicacy of Ra-223 treatment in combination 
or sequence with recently approved drugs such as abiraterone acetate, enzalutamide 
and sipuleucel-T [41-43]. Ra-223 therapy is currently not approved in Italy for use 
in association to chemotherapy, due to the concern for additive myelosuppression 
effect. However, it is likely that this limitation will be overcome after the ϐindings of 
a completed phase I-IIa clinical trial that evaluated safety of Ra-223 plus docetaxel 
vs docetaxel alone [44]. Unlike systemic therapies with beta-emitting radionuclides, 
Ra-223 therapy does not raise signiϐicant concerns about external radiation exposure, 
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allowing drug administration in an outpatient setting. This practical aspect, in 
association with the proven efϐicacy and safety of this novel radiopharmaceutical, 
will probably result in an extensive use of Ra-223 dichloride in CRPC patients with 
symptomatic bone metastases. 
In this new scenario, it is important to identify the most appropriate subgroup of 
CRPC patients eligible for Ra-223 dichloride treatment. Due to the signiϐicant beneϐit 
on Overall Survival, there is growing interest in introducing Ra-223 dichloride in an 
upfront therapeutic setting, involving asymptomatic or mildly symptomatic mCRPC 
patients who would receive a major beneϐit from Ra-223. It has been shown, in fact, 
that patients who have been extensively pre-treated or characterized by a baseline 
ECOG PS≥2 present a higher risk of grade 3-4 hematologic adverse events during Ra-
223 treatment [45]. 
Given the favorable toxicity proϐile of this treatment, extended and higher-dose 
therapeutic regimens are currently under evaluation. Results of a recent prospective 
clinical trial reported that Ra-223 re-treatment is safe and provides control of bone 
disease progression, while the phase I dose-escalation protocol investigating Ra-
223 tolerability found that there are no major concerns on hematologic toxicity in 
administration of activities up to 250 kBq/kg [46,47]. On this basis, a prospective trial 
is currently enrolling patients to evaluate safety and efϐicacy of 6 administations of 80 
kBq/kg of Ra-223 dichloride versus standard activity [48]. Recently, feasibility of bone 
lesion dosimetry in patients undergoing Ra-223 treatment has been conϐirmed [49]. 
In this evolving scenario, the possibility to evaluate Ra-223 Absorbed Dose to bone 
lesions could lead, in the future, to a dosimetry-based therapeutic approach with Ra-
223 activities tailored on patients’ bone lesion biokinetics. In addition to that, beyond 
prostate cancer, potential use of Ra-223 dichloride is currently under evaluation in 
other bone-metastatic neoplasms such as breast, thyroid and renal cancer [50-52]. 
Results of these promising clinical trials may help clarifying the optimal sequencing of 
new therapeutic possibilities for metastatic Castration-Resistant Prostate Cancer and 
the appropriate eligibility criteria for Ra-223 treatment in oncologic patients.
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